摘要
目的:探讨125I粒子联合化疗治疗非小细胞肺癌(NSCLC)的临床效果及并发症。方法:治疗组(42例)采用CT引导下、PD(处方剂量)=8~10Gy/h植入125I粒子,3 d后紫杉醇+DDP静脉化疗,对照组(46例)单纯紫杉醇+DDP静脉化疗,药物剂量与治疗组参考标准相同。2个月后观察治疗效果(CR,PR,SD,PD)。根据生活质量量表EORTC QLQ-C30评价生活质量。结果:技术成功率100%,术后随访率100%。治疗组CR 4例(9.5%),PR 14例(33.3%),SD 20例(47.6%),PD4例(9.5%),CR+PR为42.9%;对照组:CR 1例(2.2%),PR 8例(17.4%),SD 22例(47.8%),PD 15例(32.6%),CR+PR为19.6%,治疗组总有效率明显高于对照组(P<0.05)。结论:对于非小细胞肺癌,125I粒子联合化疗具有优势互补作用,有利于短期内降低肿瘤负荷,提高近期疗效。
Objective ：To evaluate the clinical efficacy of ^125Ⅰ seed implantation combined with chemotherapy in the treatment of non-small cell lung carcinoma （ NSCLC ） and its complications. Methods： Combined treatment group （ n = 42 ） received CT-guided interstitial ^125Ⅰ seed implantation （PD --8-10 Gy/h）, and three days later they were given TAX ＋ DDP intravenous chemotherapy. Control group （ n = 46 ） only received TAX ＋ DDP chemotherapy. The dosage was selected based on the same reference standard as the treatment group. The therapeutic efficacy was observed two months later. The life quality of patients was evaluated by using EORTC QLQ-C30 table. Results：Both the technical success rate and follow-up rate were all 100%. In combined treatment group 4 patients achieved complete response （CR, 9.5% ） , 14 patients had partial response （PR, 33.3% ） , 20 patients with stable disease （SD, 47.6% ） and 4 patients with progressed disease （PD, 9.5% ）. The total response rate （ CR ＋ PR） was 42.9%. In control group 1 patient achieved complete response （2.2%） , 8 patients had partial response （ 17.4% ）, 22 patients with stable disease （47.8%） and 15 patients with progressed disease （32.6%）. The total response rate （ CR ＋ PR） was 19.6%. The total response rate of the treatment group was significantly higher than control group. Conclusion： ^125Ⅰ seed implantation is synergistic with chemotherapy which is beneficial in reducing tumor load in a short period and increased the short β2-MG term therapeutic efficacy for NSCLC.
出处
《肿瘤》
CAS
CSCD
北大核心
2007年第5期406-408,共3页
Tumor
